Orilissa (Elagolix Sodium) Patent Expiration, LOE Window & CMS Spending

Orilissa (Elagolix Sodium) by AbbVie: FDA Orange Book core substance LOE 2039-07-23 (last listed 2040-08-27), 0 AB generics, $28.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN210450 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-07-23
Last Listed Patent or Exclusivity Date2040-08-27
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$28.3M
2024 Medicare Part D Spend$3.2M
2024 Medicaid Spend$25.2M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 21.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.